Can an Immune-Modulating drug clear Alzheimer's brain plaques?
Disease control
Recruiting now
This phase 2 trial investigates whether ozanimod, an oral drug that regulates the immune system, can reduce brain amyloid plaques and inflammation in people with moderate Alzheimer's disease. Forty participants aged 55 to 80 will receive either ozanimod or standard Alzheimer's me…
Phase: PHASE2 • Sponsor: ChenXiaoChun • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC